Drug Trial Radar · NCT00200460
A Study Evaluating the Effects of Nebivolol on Blood Pressure in Hypertensive Patients
Last checked: Nov 20, 2026Latest source record: Sep 20, 2005 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
825
Actual
Start
Sep 2001
Primary completion
Not stated
Study completion Mar 2003
Sponsor
- Lead sponsor
- Mylan Bertek PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Sep 20, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effects of various doses of nebivolol in patients with mild to moderate hypertension.
Conditions
- Hypertension
Interventions
NebivololDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The change of the average sitting diastolic blood pressure taken at trough drug plasma level at the end of treatment compared to baseline
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mylan Pharmaceuticals Inc.
Morgantown, West Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.